Alert detail

LCD L39650: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules — CGS Administrators

Policy ID: LCD-L39650Specialty: OutpatientAdded: 6/5/2026Effective: May 28, 2026lcd
High

What changed

New LCD for thyroid nodule risk stratification testing.

Who’s affected: Outpatient billing teams · Effective: May 28, 2026

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 2 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Outpatient policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Outpatient audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Outpatient— the week’s changes and deadlines, delivered to your inbox. No account required.